 Moderna shares rose by almost 20 overnight in the US an experimental cancer vaccine based on its messenger RNA MRNA technology boosted survival rates by over 40 in a trial. Shares in pharma companies working on other mRNA-based therapies also jumped on the news with Moderna boss Paul Burton saying the results had the capacity to be a new paradigm in the treatment of cancer. 